Re-appointment of M/s. Dhara Patel, peer reviewed Company Secretary Firm as the Secretarial Auditor of the Company for five financial years commencing from F.Y. 2026-27
CORONA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Corona Remedies Limited held a Board meeting on May 11, 2026 approving several items. The company reported strong FY2026 financials with revenue from operations of Rs. 1,403.18 Crores (up from Rs. 1,196.42 Crores), and net profit after tax of Rs. 184.85 Crores (up from Rs. 149.05 Crores), representing approximately 24% growth. The Board recommended a final dividend of Rs. 10 per share (100%) for FY 2025-26, payable by August 7, 2026, subject to shareholder approval. Multiple auditor appointments were approved including new statutory auditor M/s. Walker Chandiok & Co LLP for five years, and re-appointment of secretarial auditor M/s. Dhara Patel for five years starting FY 2026-27. Dr. Kirtikumar Mehta was also re-appointed as Non-Executive Director and Chairman for five years from April 1, 2027.
The filing shows healthy financial growth and routine governance appointments. The dividend recommendation and strong profit growth are positive signals for shareholders. The multiple auditor appointments reflect normal rotation practices with no red flags.